trial summary · NCT07444541
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Pancreatic Cancer, sponsored by Anova Innovation Limited. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
Source record: https://clinicaltrials.gov/study/NCT07444541
Facts
| registry id | NCT07444541 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Pancreatic Cancer |
| sponsor | Anova Innovation Limited |
| sponsor class | INDUSTRY |
| enrollment | 84 |
| start date | 2026-12 |
| primary completion | 2027-08 |
| completion | 2028-12 |
| results posted | not reported |
Conditions
- Pancreatic Cancer
Interventions
- ANO31905
- AG [gemcitabine+nab-paclitaxel]
- mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.